Results 161 to 170 of about 3,107,135 (285)

Xenbase: 25 years of integrating molecular and biomedical data from Xenopus. [PDF]

Genetics
Chu S, Bell AJ, Lotay V, Ly N, Pells TJ, Kwon T, Agalakov S, Ponferrada V, Lenz C, James-Zorn C, Arshinoff B, Segerdell E, Wang D, Thorner K, Wasmuth JD, Fisher M, Karimi K, Zorn AM, Vize PD.   +18 more
europepmc   +1 more source

A Systematic Review and Meta‐Analysis of the Recurrence of Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune encephalitis (AE) is a disease with a potential for recurrence, and patients receive immunotherapy to prevent it. However, there is no consensus on the duration of immunotherapy. This study aimed to determine the recurrence rate and identify the risk factors for AE to provide guidance on the duration of immunotherapy ...
Shangkai Bai, Sen Zhang, Haipei Zhang, Yating Zhang, Junhong Guo, Xiaoyan Yang   +5 more
wiley   +1 more source

Global Pharmacovigilance of Aesthetic Botulinum Toxin Type A: Analysis of Adverse Event Reports From the USA, Europe, Canada, and Australia. [PDF]

J Cosmet Dermatol
Zargaran A, Zargaran D, Pirayesh A, Woollard A, Mosahebi A.   +4 more
europepmc   +1 more source

Innate Immune Reprogramming Mediated by Endogenous Retroelement Dysregulation Drives Multiple Sclerosis Progression

Annals of Clinical and Translational Neurology, EarlyView.
Epigenetic reprogramming in hematopoietic stem and progenitor cells (HSPCs) and downstream myeloid cells, mediated by H3.3 downregulation and endogenous retroelement (ERE) overexpression, contributes to the progression of multiple sclerosis (MS). ABSTRACT Background Skewed myelopoiesis in the bone marrow has been identified as a key driver of multiple ...
Li‐Mei Xiao, Qiu‐Ping Zhao, Run‐Yun Li, Wei Chen, Huan‐Huan Song, Wan‐Jin Chen, Ying Fu   +6 more
wiley   +1 more source

The billion-dollar case for sustaining palaeontology's digital databases. [PDF]

Nat Ecol Evol
Dowding EM, Dunne EM, Collins KS, Cryer K, De Baets K, Dimitrijević D, Edie SM, Finnegan S, Kiessling W, Lintulaakso K, Liow LH, Little H, Na L, Peters SE, Renaudie J, Saupe EE, Seuss B, Sessa JA, Smith JA, Uhen MD, Williams JW, Kocsis ÁT.   +21 more
europepmc   +1 more source

Cache Modelling in a Performance Evaluator of Parallel Database Systems [PDF]

, 1997
Burger, Albert Georg, Taylor, Hamish, Tomov, Neven, Zhou, S.   +3 more
core  

Location‐Specific Hematoma Volume Predicts Early Neurological Deterioration in Supratentorial ICH

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Early neurological deterioration (END) adversely affects outcomes in patients with intracerebral hemorrhage (ICH). This study aimed to determine the location‐specific hematoma volumes for END in supratentorial ICH patients. Methods We retrospectively analyzed supratentorial ICH patients presenting from two prospective cohorts.
Zuoqiao Li, Guilin Meng, Zijie Wang, Xiao Hu, Jing Cheng, Chu Chen, Tiannan Yang, Jiaxin Luo, Zizhen Meng, Xueyun Liu, Qi Li   +10 more
wiley   +1 more source

Von Economo Neuron Loss in Frontotemporal Dementia: A Meta‐Analysis of Neuropathological Studies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Von Economo neurons (VENs) have been reported to be vulnerable to neurodegeneration in frontotemporal dementia (FTD), particularly the behavioral variant (bvFTD), but these findings have not been systematically assessed across independent brain banks.
Daniel Talmasov, Alexander F. Santillo, Patrick R. Hof   +2 more
wiley   +1 more source

Recommendations for HLA Genotyping Data Standards and Clinical Laboratory Staffing Considerations. [PDF]

HLA
Spierings E, Brown NK, Latham K, Robinson J, Melchers M, Askar M, Morris GP, Weimer E, Maiers M, Madbouly A.   +9 more
europepmc   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source